Abstract: The use of compositions comprising a papaya mosaic virus (PapMV) moiety for stimulation of the innate immune response is provided. The PapMV moiety may be papaya mosaic virus or PapMV virus-like particles (VLPs). The PapMV compositions stimulate a sufficiently strong innate immune response to provide protection against subsequent pathogen challenge or to treat an established infection. The use of PapMV compositions to protect a subject from potential infection by a pathogen, such as a viral pathogen, a bacterial pathogen or a fungal pathogen, and the use of PapMV compositions to treat an established infection, are also provided. The PapMV compositions be administered, for example, via intranasal or pulmonary routes to elicit effects within the mucosa and/or in the respiratory system.

Abstract: An in vitro process of preparing virus-like particles (VLPs) from recombinant papaya mosaic virus coat protein and ssRNA, which allows for large scale production of VLPs in high yields, is provided. Also provided are VLPs comprising ssRNA prepared by the in vitro process. The VLPs can be used as adjuvants and when fused to an antigen, as vaccines. The use of the VLPs for stimulation of the innate immune response is also provided.

Abstract: Papaya mosaic virus and virus-like particles (VLPs) comprising ssRNA for use to inhibit cancer growth and metastasis. The PapMV and PapMV VLPs may be used alone or in combination with another cancer therapy, such as a chemotherapeutic, immunotherapeutic, or radiotherapy.

Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.

Abstract: Recombinant papaya mosaic virus (PapMV) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the M2e peptide, fused at a position within a predicted random coil within 13 amino acids of the N-terminus of the coat protein, uses thereof to prepare virus-like particles (VLPs), and uses of the VLPs in influenza vaccines.

Abstract: An in vitro process of preparing virus-like particles (VLPs) from recombinant papaya mosaic virus coat protein and ssRNA, which allows for large scale production of VLPs in high yields, is provided. Also provided are VLPs comprising ssRNA prepared by the in vitro process. The VLPs can be used as adjuvants and when fused to an antigen, as vaccines. The use of the VLPs for stimulation of the innate immune response is also provided.

Abstract: The use of compositions comprising a papaya mosaic virus (PapMV) moiety for stimulation of the innate immune response is provided. The PapMV moiety may be papaya mosaic virus or PapMV virus-like particles (VLPs). The PapMV compositions stimulate a sufficiently strong innate immune response to provide protection against subsequent pathogen challenge or to treat an established infection. The use of PapMV compositions to protect a subject from potential infection by a pathogen, such as a viral pathogen, a bacterial pathogen or a fungal pathogen, and the use of PapMV compositions to treat an established infection, are also provided. The PapMV compositions be administered, for example, via intranasal or pulmonary routes to elicit effects within the mucosa and/or in the respiratory system.

Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.

Abstract: An affinity-conjugated antigen system (ACAS) comprising one or more antigens conjugated via a plurality of affinity moieties to a papaya mosaic virus (PapMV) or virus-like particle (VLP) derived from the coat protein of PapMV is provided. The affinity moieties are molecules or compounds that are capable of specifically binding to the antigen(s) of interest and which can be attached, for example by chemical or genetic means, to the coat protein of the PapMV or PapMV VLP. The ACAS can optionally further comprise one or more additional antigens, which may be the same as, or different to, the conjugated antigen(s) comprised by the ACAS. Also provided are immunogenic compositions, including vaccines, comprising an ACAS. The immunogenic compositions are useful in the treatment, including prevention, of various diseases and disorders for which a humoral and/or cellular response in the animal is required.

Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.

Abstract: The invention concerns in particular a system comprising: a first terminal (1); a second terminal (21 or 22 or 23); at least a first messaging system (31 or 32 or 33) able to transmit, to the second terminal, at least the message body of a message (10) from the first terminal; at least one device (4) controlling at least one condition (11), at least once, the said control device allowing the first messaging system to transmit to the second terminal at least the message body of the said message if the condition control result is positive, the said control device preventing the first messaging system from transmitting to the second terminal at least the message body of the said message if the condition control is negative, at least during the time for which the condition control result remains negative; at least one data server (51 or 52 or 53 or 54) external to the control device; at least one link providing communication through the Internet between on the hand the external server, or at least one of the exte

Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.

Abstract: A multivalent vaccine composition that comprises a papaya mosaic virus (PapMV) component and one or more antigens is provided. The composition can further optionally comprise a Salmonella spp. porin component. The PapMV component can be PapMV or PapMV virus-like particles (VLPs). The porin component can be a Salmonella spp. OmpC, OmpF or a combination thereof, and can be combined with the PapMV component or conjugated to the PapMV component. The PapMV component in the multivalent vaccine composition functions as an adjuvant and/or an immunostimulant with respect to the one or more antigens. Use of the multivalent vaccine compositions to provide protection against a plurality of strains of a pathogen, or against more than one pathogen, are also provided.

Abstract: Adjuvants comprising OmpC porin, OmpF porin, or a combination thereof, are provided. The adjuvants can be administered to a subject in combination with antigenic material in order to potentiate the immunogenic effect of the antigenic material. Also provided are products comprising antigenic material in combination with OmpC and/or OmpF, including products comprising a pre-formulated vaccine in combination with OmpC and/or OmpF. Further provided is the use of OmpC and/or OmpF to improve the effect of a pre-formulated vaccine.

Abstract: The immunogenic properties of the potexvirus MaI va mosaic virus (MaMV) and virus-like particles (VLPs) comprising the coat proteins of MaMV are disclosed VLPs prepared from MaMV coat proteins, methods of preparing the VLPs, MaMV coat protein polypeptides and polynucleotides encoding the coat protein are taught. Further, immunogenic compositions comprising MaMV or a VLP comprising the MaMV coat protein alone or in combination with one or more antigens and the use of said compositions to vaccinate and/or induce an immune response in an animal are also taught.

Abstract: An antigen-presenting system (APS) comprising one or more enterobacterial antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. The PapMV or VLP included in the APS is capable of potentiating an immune response against said one or more enterobacterial antigens. The APS can be used, for example, as a vaccine against enterobacterial disease, such as typhoid fever. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PapMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP), or the APS can comprise both conjugated and non-conjugated antigens. Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means.

Abstract: An antigen-presenting system (APS) comprising one or more antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. Specifically an APS comprising one or more influenza virus antigens is provided. The APS can be used, for example, as a vaccine against influenza. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PaPMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP). Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means.

Abstract: An affinity-conjugated antigen system (ACAS) comprising one or more antigens conjugated via a plurality of affinity moieties to a papaya mosaic virus (PapMV) or virus-like particle (VLP) derived from the coat protein of PapMV is provided. The affinity moieties are molecules or compounds that are capable of specifically binding to the antigen(s) of interest and which can be attached, for example by chemical or genetic means, to the coat protein of the PapMV or PapMV VLP. The ACAS can optionally further comprise one or more additional antigens, which may be the same as, or different to, the conjugated antigen(s) comprised by the ACAS. Also provided are immunogenic compositions, including vaccines, comprising an ACAS. The immunogenic compositions are useful in the treatment, including prevention, of various diseases and disorders for which a humoral and/or cellular response in the animal is required.

Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.

Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.